Evidence map›Paper›PMID 40556750›Full record

ArticleEndocrine oncology (Bristol, England)2025

Real-world lenvatinib use in metastatic thyroid cancer: early dose intensity and side effect profile in an Australian centre.

Monica Majumder, Shejil Kumar, Tony Lian, Venessa H M Tsang, Meredith Oatley, Lyndal Tacon, Bruce G Robinson, Anthony Glover, Roderick J Clifton-Bligh, Matti L Gild

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Monica MajumderDepartment of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-9796-4687
Shejil KumarDepartment of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Tony LianFaculty of Medicine & Health, University of Sydney, Sydney, New South Wales, Australia.
Venessa H M TsangDepartment of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Meredith OatleyNorthern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Lyndal TaconDepartment of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Bruce G RobinsonDepartment of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Anthony GloverFaculty of Medicine & Health, University of Sydney, Sydney, New South Wales, Australia.
Roderick J Clifton-BlighDepartment of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-1545-0368
Matti L GildDepartment of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Lenvatinib is a multi-kinase inhibitor approved in radioiodine-refractory thyroid cancer based on results of a phase III trial. Real-world data have emphasised concerns regarding tolerability of the starting dose (24 mg/day) and frequency of dose-limiting treatment-related adverse effects (TRAEs). We aimed to assess early dose intensity, tolerability and efficacy using lenvatinib in metastatic thyroid cancer patients in an Australian centre. Design/Methods: Retrospective medical record review was conducted of patients with advanced/metastatic differentiated, medullary and anaplastic thyroid cancer on lenvatinib at a quaternary referral centre (2014-2023). Results: 64 patients were included. Median age at lenvatinib commencement was 67 years (range 38-92). 53% were female. The most common non-nodal metastases were pulmonary (86.4%) and skeletal (50.8%). Most patients commenced lenvatinib at 24 mg/day (48/53; 90.5%), with fewer than half maintaining this dose by 8 weeks (21/45; 46.7%). Those who maintained the 24 mg dose at 8 weeks were younger at lenvatinib commencement (62 years vs 71 years, Conclusion: This real-world analysis demonstrates difficulties in maintaining early lenvatinib dose intensity, with frequent TRAEs. Greater emphasis on supportive care is needed to maximise early dose intensity and efficacy.

Indexed as

lenvatinibradio-iodine refractorythyroid cancertyrosine kinase inhibitors

Identifiers

PMID40556750
PMCPMC12186296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.